Innovating to improve health worldwide

Global biopharmaceutical CEOs response to reforms introduced in Germany

In response to reforms adopted by the German government on 10 July, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively...

Statement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement

On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement.

WIPO, IFPMA and Interpat join forces to support health innovation through IP management clinics

The World Intellectual Property Organization (WIPO), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Interpat have launched a new partnership that underlines a shared commitment to intellectual property supporting health innovation.

Global biopharmaceutical CEOs response to reforms introduced in Germany

On 30 June, in response to reforms introduced in Germany, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation introduced by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Pricing and reimbursement policies which fail to reflect the value that medicines and...